septemb
januari
world
health
organ
receiv
report
countri
laboratoryconfirm
case
human
middl
east
respiratori
syndrom
mer
caus
infect
mer
coronaviru
merscov
least
relat
death
case
merscov
infect
continu
occur
includ
sporad
zoonot
infect
human
across
arabian
peninsula
occasion
import
associ
cluster
region
outbreak
nonsustain
humantohuman
transmiss
health
care
set
dromedari
camel
consid
like
sourc
animaltohuman
transmiss
merscov
enter
host
cell
bind
dipeptidyl
peptidas
receptor
carcinoembryon
antigenrel
celladhes
molecul
cofactor
ligand
replic
effici
human
respiratori
epithelium
ill
begin
incub
period
day
frequent
result
hypoxem
respiratori
failur
need
multiorgan
support
howev
asymptomat
mild
case
also
occur
realtim
reversetranscriptionpolymerasechainreact
rtpcr
test
respiratori
secret
mainstay
diagnosi
sampl
lower
respiratori
tract
greatest
yield
among
serious
ill
patient
antivir
therapi
proven
efficaci
thu
treatment
remain
larg
support
potenti
vaccin
earli
development
stage
multipl
gap
knowledg
regard
evolut
transmiss
viru
diseas
pathogenesi
treatment
prospect
vaccin
ongo
occurr
mer
human
associ
high
mortal
call
continu
collabor
approach
toward
gain
better
understand
infect
human
anim
merscov
first
identifi
septemb
patient
saudi
arabia
hypoxem
respiratori
failur
multiorgan
ill
subsequ
case
includ
infect
human
across
arabian
peninsula
occasion
import
associ
cluster
region
outbreak
nonsustain
humantohuman
transmiss
health
care
set
fig
januari
receiv
report
countri
case
laboratoryconfirm
mer
least
relat
death
percentag
fatal
case
approxim
report
case
link
exposur
saudi
arabia
fig
transmiss
merscov
dromedari
camel
human
document
sever
countri
humantohuman
transmiss
health
care
set
account
major
report
case
date
although
humantohuman
transmiss
household
set
also
identifi
fig
seroepidemiolog
studi
shown
antibodi
merscov
present
dromedari
camel
camelu
dromedariu
throughout
middl
east
africa
studi
indic
merscov
circul
among
dromedari
least
three
decad
although
merscov
rna
detect
respiratori
bodili
secret
particularli
among
juvenil
dromedari
infect
dromedari
may
caus
mild
upper
respiratori
manifest
investig
anim
close
proxim
report
case
human
support
theori
dromedari
like
sourc
animaltohuman
transmiss
one
casecontrol
studi
show
person
present
communityacquir
mer
time
like
control
direct
exposur
dromedari
preced
week
addit
seroepidemiolog
studi
indic
infect
may
associ
occup
exposur
dromedari
one
studi
conduct
saudi
arabia
rate
merscov
seroposit
time
high
shepherd
time
high
slaughterhous
worker
gener
popul
high
sequenc
homolog
virus
sporad
case
human
implic
dromedari
although
rout
transmiss
remain
unclear
appear
includ
contact
infecti
nasal
bodili
secret
possibl
consumpt
raw
dromedari
product
eg
unpasteur
milk
although
dromedarytohuman
transmiss
merscov
well
recogn
direct
exposur
dromedari
document
primari
case
detail
see
tabl
supplementari
appendix
avail
full
text
articl
nejmorg
humantohuman
transmiss
appear
infrequ
outsid
health
care
set
document
close
household
contact
infect
person
among
household
contact
evalu
studi
conduct
saudi
arabia
posit
result
merscov
realtim
rtpcr
assay
serolog
assay
one
household
cluster
extend
famili
member
affect
risk
factor
infect
includ
sleep
index
patient
room
touch
respiratori
secret
index
patient
littl
household
transmiss
detect
countri
merscov
infect
report
sustain
humantohuman
transmiss
document
countri
date
one
seroepidemiolog
studi
conduct
saudi
arabia
use
sampl
collect
show
antibodi
merscov
present
particip
find
suggest
unrecogn
infect
may
occur
outbreak
jeddah
saudi
arabia
mer
case
report
asymptomat
role
person
asymptomat
infect
humantohuman
transmiss
remain
unclear
may
underappreci
increasingli
sensit
surveil
strategi
followup
contact
contribut
increas
recognit
asymptomat
case
health
care
set
earliest
case
mer
identifi
retrospect
hospitalassoci
cluster
jordan
april
transmiss
within
health
care
set
remain
promin
epidemiolog
featur
mer
mer
outbreak
jeddah
affect
patient
health
care
personnel
affect
patient
health
care
personnel
admit
visit
health
care
facil
within
day
symptom
onset
nosocomi
outbreak
occur
health
care
facil
jordan
south
korea
saudi
arabia
korean
outbreak
largest
outbreak
outsid
middl
east
transmiss
singl
infect
person
led
case
death
case
fatal
rate
across
multipl
health
care
facil
overcrowd
emerg
depart
delay
diagnosi
substandard
practic
infect
control
identifi
contribut
factor
outbreak
occur
health
care
set
avail
epidemiolog
observ
suggest
humantohuman
transmiss
occur
primarili
close
contact
patient
confirm
mer
like
respiratori
droplet
risk
transmiss
appear
greater
perform
aerosolgener
procedur
without
adequ
person
protect
proper
room
ventil
addit
contamin
environment
surfac
patient
room
merscov
may
result
transmiss
one
studi
isol
infecti
viru
air
sampl
mer
isol
ward
although
find
requir
confirm
person
mer
identifi
region
arabian
peninsula
either
recent
travel
arabian
peninsula
contact
someon
return
arabian
peninsula
despit
larg
number
person
visit
saudi
arabia
yearli
hajj
umrah
pilgrimag
pilgrimagerel
case
mer
report
although
two
dutch
pilgrim
return
hajj
data
world
health
organ
collect
decemb
time
total
number
case
countri
case
countri
case
countri
case
countri
case
unit
state
unit
kingdom
philippin
south
korea
china
arabia
malaysia
thailand
germani
tunisia
austria
algeria
jordan
greec
franc
itali
egypt
oman
bahrain
new
england
journal
medicin
download
nejmorg
univers
edinburgh
lib
februari
person
use
use
without
permiss
copyright
massachusett
medic
societi
right
reserv
ceiv
diagnosi
mer
sourc
infect
remain
unclear
member
travel
tour
group
report
visit
camel
market
consum
raw
camel
milk
activ
unrel
hajj
saudi
arabian
author
ban
presenc
camel
near
holi
site
minim
exposur
potenti
infect
camel
major
sever
mer
case
occur
adult
older
year
age
coexist
condit
diabet
hypertens
cardiac
diseas
obes
chronic
respiratori
diseas
endstag
renal
diseas
cancer
person
receiv
immunosuppress
therapi
tabl
supplementari
appendix
older
age
chronic
respiratori
ill
associ
death
among
infect
patient
mild
asymptomat
infect
occur
predominantli
among
young
healthi
person
includ
health
care
worker
clinic
recogn
infect
among
children
uncommon
host
genet
risk
factor
document
date
virolog
merscov
sixth
coronaviru
first
betacoronaviru
c
phylogenet
lineag
known
infect
human
replic
hostcel
cytoplasm
sixteen
nonstructur
protein
serv
role
replic
includ
novel
rna
proofread
exonucleas
regul
replic
fidel
tabl
supplementari
appendix
merscov
tropism
determin
primarili
bind
viru
spike
glycoprotein
cellsurfac
molecul
fig
attach
entri
facilit
recent
discov
cellular
cofactor
spike
glycoprotein
activ
fusogen
form
hostcel
transmembran
serin
proteas
endosom
cathepsin
furin
suggest
multipl
possibl
pathway
spike
matur
viral
entri
cell
virion
assembl
circul
strain
human
merscov
date
appear
repres
singl
serotyp
serum
convalesc
patient
mer
neutral
monoclon
antibodi
receptorbind
site
spike
glycoprotein
inhibit
infect
cell
viru
human
pathogenesi
wide
express
human
cell
includ
fibroblast
intestin
epitheli
cell
hepatocyt
weak
express
lung
pattern
express
specif
cell
type
geneexpress
atla
small
number
tissu
detect
express
includ
tissu
trachea
throat
small
intestin
colon
appendix
find
consist
observ
merscov
shown
replic
well
human
cell
line
deriv
respiratori
intestin
epithelium
ex
vivo
model
human
lungtissu
infect
express
merscov
antigen
viral
particl
found
bronchial
epitheli
cell
type
type
ii
alveolar
pneumocyt
vascular
endotheli
cell
result
cell
death
diffus
alveolar
damag
fig
alveolar
macrophag
appear
rel
spare
similar
pattern
distribut
viral
replic
seen
nonhuman
primat
model
viral
kinet
merscov
rna
detect
frequent
higher
viral
load
sampl
lower
respiratori
tract
sampl
upper
respiratori
tract
persist
patient
particularli
sever
ill
patient
month
merscov
rna
also
detect
blood
serum
sampl
one
third
patient
present
mer
posit
test
merscov
rna
blood
associ
greater
need
mechan
ventil
extracorpor
respiratori
support
higher
mortal
merscov
rna
detect
occasion
stool
patient
mer
urin
avail
anim
model
merscov
infect
reliabl
recapitul
sever
human
infec
tion
laboratori
rodent
includ
mice
suscept
merscov
howev
merscov
suscept
mice
describ
transduct
adenoviru
vector
express
human
version
similar
human
transgen
mous
express
human
receptor
primarili
pulmonari
diseas
rhesu
macaqu
marmoset
inocul
respiratori
tract
merscov
induc
clinic
diseas
vari
sever
rhesu
macaqu
selflimit
pneumonia
develop
incub
period
hour
studi
marmoset
shown
extens
lung
diseas
viru
replic
detect
merscov
rna
multipl
organ
blood
associ
death
howev
anoth
studi
could
reproduc
experiment
induc
ill
marmoset
insight
pathobiolog
mer
limit
princip
autopsi
find
patient
mer
die
approxim
day
onset
ill
diffus
alveolar
damag
doublestain
immunoassay
show
merscov
antigen
pneumocyt
epitheli
syncyti
cell
evid
extrapulmonari
merscov
antigen
detect
even
kidney
despit
fact
renal
insuffici
common
clinic
find
among
critic
ill
patient
examin
infect
mice
express
human
receptor
show
effect
interferon
signal
cellmedi
immun
requir
viral
clearanc
similar
coronavirus
mani
pathogen
merscov
subvert
hostcel
pathway
nonstructur
protein
cleav
replicas
polyprotein
directli
target
hostcel
function
immun
respons
addit
merscov
uniqu
set
accessori
gene
sever
may
contribut
immun
evas
virul
eg
immuneevas
protein
sarscov
protein
reduc
signal
signal
transduc
activ
transcript
milieu
cytokin
bronchoalveolar
lavag
fluid
serum
studi
two
patient
mer
one
patient
surviv
persist
viral
detect
blunt
express
antivir
sens
respons
factor
retino
acidinduc
gene
interferon
regulatori
factor
interferon
alfa
bronchoalveolar
lavag
fluid
patient
surviv
high
level
antivir
factor
bronchoalveolar
lavag
fluid
achiev
rapid
viral
clearanc
antivir
factor
part
innat
antivir
respons
induc
earli
cell
expos
merscov
kinet
durabl
specif
antibodi
respons
merscov
fulli
character
patient
produc
serum
igg
secretori
iga
within
week
onset
ill
howev
presenc
antibodi
necessarili
follow
elimin
merscov
rna
lower
respiratori
tract
although
data
titer
infecti
viru
site
lack
declin
antibodi
level
period
sever
month
observ
convalesc
patient
patient
symptomat
mer
present
incub
period
day
mildli
symptomat
case
manifest
lowgrad
fever
runni
nose
sore
throat
muscl
ach
sever
diseas
character
progress
panel
show
structur
ecolog
featur
transmiss
pattern
middl
east
respiratori
syndrom
mer
coronaviru
merscov
virion
surfac
cover
spike
glycoprotein
kda
glycoprotein
extend
outward
creat
crownlik
appear
spike
glycoprotein
critic
bind
hostcel
receptor
dipeptidyl
peptidas
initi
infect
dromedari
camel
infect
viru
believ
like
sourc
animaltohuman
transmiss
humantohuman
transmiss
household
health
care
set
also
occur
panel
b
show
current
understand
key
event
mer
pathogenesi
base
limit
observ
patient
data
anim
cellcultur
model
system
intratrach
inocul
merscov
nonhuman
primat
viru
infect
bronchial
epitheli
cell
spread
lung
parenchym
cell
includ
type
type
ii
alveolar
pneumocyt
endotheli
cell
viral
entri
facilit
anoth
cellsurfac
protein
carcinoembryon
antigenrel
celladhes
molecul
also
express
lung
tissu
inflammatori
signal
molecul
releas
infect
cell
alveolar
macrophag
neutrophil
recruit
infect
tissu
detect
infect
patient
black
text
anim
model
blue
text
host
antivir
type
type
iii
interferon
respons
occur
system
releas
proinflammatori
cytokin
chemokin
viru
may
spread
circul
possibl
lung
parenchyma
infect
endotheli
cell
human
high
viral
copi
number
detect
lower
respiratori
tract
includ
tracheal
aspir
bronchoalveolar
lavag
specimen
well
peripher
blood
advanc
diseas
diffus
alveolar
damag
seen
extens
hemorrhag
edema
hyalin
membran
deposit
denot
cxc
motif
chemokin
il
interleukin
receptor
antagonist
ifn
interferon
mcp
monocyt
chemotact
protein
new
england
journal
medicin
download
nejmorg
univers
edinburgh
lib
februari
person
use
use
without
permiss
copyright
massachusett
medic
societi
right
reserv
acut
respiratori
distress
syndrom
median
day
hospit
admiss
intens
care
unit
sever
ill
patient
chest
radiograph
comput
tomograph
scan
often
show
multilobar
airspac
diseas
groundglass
opac
occasion
pleural
effus
thorac
imag
usual
normal
patient
mild
ill
extrapulmonari
manifest
common
among
sever
ill
patient
one
third
critic
ill
patient
gastrointestin
symptom
nausea
vomit
diarrhea
acut
kidney
injuri
report
half
critic
ill
patient
stillbirth
report
pregnant
woman
probabl
mer
neurolog
manifest
suggest
enceph
report
three
case
laboratori
find
typic
includ
leukopenia
lymphopenia
occasion
includ
thrombocytopenia
anemia
mildtomoder
elev
aminotransferas
level
common
especi
among
critic
ill
patient
detail
see
fig
tabl
supplementari
appendix
clinic
featur
mer
often
differ
acut
febril
respiratori
ill
pneumonia
therefor
diagnost
workup
mer
patient
acut
respiratori
ill
without
fever
guid
presenc
clinic
suspicion
epidemiolog
link
fig
tabl
supplementari
appendix
mer
suspect
immedi
precaut
infect
control
taken
specimen
upper
lower
respiratori
tract
collect
realtim
rtpcr
analysi
specimen
lower
respiratori
tract
obtain
earli
cours
ill
within
day
symptom
onset
appear
best
diagnost
sensit
repeat
test
sampl
lower
respiratori
tract
period
sever
day
increas
diagnost
yield
hospit
patient
test
serum
specimen
use
realtim
rtpcr
analysi
also
recommend
patient
present
symptom
last
day
longer
serolog
test
merscovspecif
antibodi
may
inform
diagnosi
sever
ill
patient
laboratoryconfirm
mer
coinfect
respiratori
viral
bacteri
pathogen
detect
present
appropri
diagnost
workup
perform
empir
antibiot
antivir
treatment
administ
accord
clinic
syndrom
eg
communityacquir
hospitalacquir
pneumonia
test
result
merscov
pend
detect
convent
respiratori
viral
bacteri
pathogen
deter
clinician
test
merscov
patient
high
index
suspicion
present
laboratori
confirm
mer
mean
realtim
rtpcr
assay
requir
posit
two
differ
merscov
genom
target
site
detect
singl
target
site
follow
sequenc
confirm
second
site
fig
supplementari
appendix
screen
confirmatori
molecular
assay
merscov
summar
tabl
supplementari
appendix
current
assay
target
region
upstream
envelop
gene
upe
recommend
screen
assay
target
use
confirm
mer
confirm
seroconvers
two
sampl
obtain
day
apart
twostag
approach
merscov
serolog
test
recommend
first
screen
perform
mean
enzymelink
immunosorb
assay
immunofluoresc
assay
use
recombin
merscov
spike
glycoprotein
subunit
confirmatori
test
perform
mean
immunofluoresc
assay
merscovinfect
cell
viru
neutral
assay
viru
cultur
merscov
success
isol
cell
cultur
commonli
specimen
lower
respiratori
tract
howev
viral
cultur
requir
highlevel
biocontain
facil
specif
antivir
therapi
shown
effect
treatment
mer
pre
vention
complic
organ
support
defin
current
standard
care
data
random
clinic
trial
investig
whether
use
therapeut
licens
indic
effect
patient
mer
lack
retrospect
observ
report
treatment
ribavirin
interferon
indic
consist
clinic
benefit
tabl
supplementari
appendix
metaanalysi
observ
studi
passiv
immunotherapi
sar
sever
influenza
suggest
decreas
mortal
associ
time
use
blood
product
convalesc
patient
particularli
neutral
antibodi
thu
freshfrozen
plasma
hyperimmun
intraven
immun
globulin
produc
patient
recov
mer
could
investig
therapi
howev
collect
suffici
hightit
plasma
experiment
use
may
prove
obstacl
evalu
wider
therapeut
applic
neutralizingantibodi
prepar
develop
effect
anim
model
tabl
supplementari
appendix
despit
common
use
glucocorticoid
sever
mer
ill
retrospect
analysi
involv
patient
sar
suggest
glucocorticoid
therapi
may
associ
increas
mortal
safeti
effect
glucocorticoid
patient
mer
uncertain
use
glucocorticoid
avoid
unless
indic
clinic
reason
condit
studi
context
clinic
trial
ribavirin
shown
inhibitori
effect
vitro
concentr
greatli
exceed
reach
usual
clinic
dose
nonetheless
among
rhesu
macaqu
expos
merscov
hour
previous
treatment
high
dose
ribavirin
interferon
associ
modest
antivir
effect
fewer
pulmonari
chang
treatment
marmoset
treat
lopinavirritonavir
interferon
substanti
lower
morbid
mortal
marmoset
treat
mycophenol
mofetil
untreat
control
variou
experiment
polyclon
monoclon
antibodi
peptid
construct
polymeras
inhibitor
test
anim
model
sever
earli
clinic
develop
one
placebocontrol
trial
interferon
lopinavirritonavir
recent
begun
clinicaltrialsgov
number
multipl
licens
drug
shown
antivir
effect
vitro
propos
hostdirect
therapeut
present
none
drug
recommend
treatment
mer
outsid
context
clinic
trial
detail
see
tabl
supplementari
appendix
public
health
author
includ
advoc
use
variou
nonpharmaceut
intervent
prevent
merscov
transmiss
tabl
supplementari
appendix
strategi
aim
reduc
risk
animaltohuman
transmiss
rapid
identif
case
trace
contact
cluster
associ
health
care
set
appropri
infect
control
core
compon
control
prevent
merscov
infect
candid
mer
vaccin
develop
use
human
potenti
use
dromedari
tabl
supplementari
appendix
primari
target
candid
vaccin
spike
glycoprotein
subunit
rang
vaccin
approach
includ
live
attenu
spike
protein
subunit
dna
nanoparticl
recombin
vector
construct
major
challeng
develop
vaccin
includ
identifi
appropri
anim
model
establish
humor
cellular
correl
protect
human
well
assess
potenti
upregul
harm
immun
respons
upon
subsequ
exposur
wildtyp
viru
data
chemoprophylaxi
control
studi
involv
human
lack
knowledg
mer
increas
work
requir
character
certain
eco
logic
epidemiolog
featur
merscov
includ
rout
animaltohuman
humantohuman
transmiss
sourc
infect
sporad
case
addit
better
character
dynam
merscov
viral
replic
relationship
clinic
manifest
need
assess
innat
adapt
immun
respons
possibl
host
genet
suscept
factor
autopsi
studi
essenti
inform
understand
diseas
patholog
extent
extrapulmonari
infect
press
need
evalu
potenti
therapi
vaccin
collabor
coordin
clinic
trial
conduct
across
affect
region
lower
risk
human
requir
effect
control
animaltohuman
transmiss
ideal
effect
dromedari
vaccin
lack
adequ
studi
clinic
character
diseas
pathogenesi
common
among
emerg
infecti
diseas
address
part
develop
preapprov
research
protocol
rapid
implement
respons
new
emerg
infect
continu
threat
mer
includ
sever
ill
period
nosocomi
outbreak
intern
spreadcal
enhanc
intern
collabor
address
research
prioriti
